Cargando…
Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials
Host-directed therapeutics targeting immune dysregulation are considered the most promising approach to address the unmet clinical need for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). To better understand the current clinical stu...
Autores principales: | Wu, Qun, Pennini, Meghan E, Bergmann, Julie N, Kozak, Marina L, Herring, Kristen, Sciarretta, Kimberly L, Armstrong, Kimberly L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379817/ https://www.ncbi.nlm.nih.gov/pubmed/35983268 http://dx.doi.org/10.1093/ofid/ofac381 |
Ejemplares similares
-
The Role of Macrophages in the Pathogenesis of ALI/ARDS
por: Huang, Xiaofang, et al.
Publicado: (2018) -
Advances in the use of exosomes for the treatment of ALI/ARDS
por: Liu, Chang, et al.
Publicado: (2022) -
Do the data obtained by the PiCCO system enable one to differentiate between direct ALI/ARDS and indirect ALI/ARDS?
por: Morisawa, K, et al.
Publicado: (2006) -
Macrophage-Targeted Nanomedicines for ARDS/ALI: Promise and Potential
por: Vichare, Riddhi, et al.
Publicado: (2022) -
Barriers to providing lung-protective ventilation to patients with ALI/ARDS
por: Passos, RH, et al.
Publicado: (2010)